Genmab — Februar 2022
-
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK
) in Patients with Head and Neck Squamous Cell Carcinoma
Feb 24, 2022 at 4:00 PM CET https://ir.genmab.com/news-releases/news-release-details/genmab-and-seagen-present-first-data-tisotumab-vedotin-tivdakr -
-
USA/åbning: Amerikanske indeks cirkler om korrektion efter invasion https://proinvestor.com/investornyt/786689/usa-abning-amerikanske-indeks-cirkler-om-korrektion-efter-invasion
-
Mon ikke det er et russisk cyberattack
-
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK
) in Patients with Head and Neck Squamous Cell Carcinoma https://proinvestor.com/investornyt/786700/genmab-and-seagen-present-first-data-on-tisotumab-vedotin-tivdak-in-patients-with-head-and-neck-squamous-cell-carcinoma -
Kære alle, Jeg ved, at vi står i en meget svær situation. Alligevel må jeg opfordre jer til at stille spørgsmål til Q&A. De er mere end velkomen. På forhånd tak.
-
Hvor mange i verden bruger Kaspersky mod cybersecurity…
-
Kaspersky Lab (/kæˈspɜːrski/; Russian: Лаборатория Касперского, tr. Laboratoriya Kasperskogo) is a Russian multinational cybersecurity and anti-virus provider headquartered in Moscow, Russia[1] and operated by a holding company in the United Kingdom. It was founded in 1997 by Eugene Kaspersky, Natalya Kaspersky, and Alexey De-Monderik; Eugene Kaspersky is currently the CEO. Kaspersky Lab develops and sells antivirus, internet security, password management, endpoint security, and other cybersecur
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind